# The Medicines Company clinical trials: 50 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 50 trials with The Medicines Company as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by The Medicines Company: 50 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/the-medicines-company

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 50
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 50, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 19, 2020 | NCT04592380 | Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF | The Medicines Company | Phase 3 | Withdrawn | Dyspnea, Hypertension, Acute Heart Failure | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04592380) |
| January 17, 2018 | NCT03400800 | Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol | The Medicines Company | Phase 3 | Completed | ASCVD, Risk Factor, Cardiovascular, Elevated Cholesterol | 1,617 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03400800) |
| January 16, 2018 | NCT03399370 | Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol | The Medicines Company | Phase 3 | Completed | ASCVD, Elevated Cholesterol | 1,561 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03399370) |
| January 11, 2018 | NCT03397121 | Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial... | The Medicines Company | Phase 3 | Completed | Heterozygous Familial Hypercholesterolemia, Elevated Cholesterol | 482 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03397121) |
| May 18, 2017 | NCT03159416 | A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7) | The Medicines Company | Phase 1 | Completed | Renal Impairment | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03159416) |
| November 15, 2016 | NCT02963311 | A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | The Medicines Company | Phase 2 | Completed | Homozygous Familial Hypercholesterolemia | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02963311) |
| October 5, 2016 | NCT02925416 | Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection | The Medicines Company | Phase 4 | Completed | Skin Diseases, Bacterial | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02925416) |
| June 15, 2016 | NCT02800590 | Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing... | The Medicines Company | Phase 2 | Completed | Colonoscopy | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02800590) |
| February 10, 2016 | NCT02678923 | MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of... | The Medicines Company | Phase 1/2 | Completed | Acute Coronary Syndrome | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02678923) |
| November 5, 2015 | NCT02597127 | Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) | The Medicines Company | Phase 2 | Completed | Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes | 501 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02597127) |
| October 1, 2015 | NCT02565147 | Bivalirudin Infusion for Ventricular Infarction Limitation | The Medicines Company | Phase 3 | Terminated | Acute Myocardial Infarction | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02565147) |
| June 15, 2015 | NCT02471690 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers | The Medicines Company | Phase 1 | Completed | Healthy | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02471690) |
| May 25, 2015 | NCT02452918 | A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy... | The Medicines Company | Phase 4 | Completed | Acute Bacterial Skin and Skin Structure Infection | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02452918) |
| March 23, 2015 | NCT02395653 | Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants | The Medicines Company | Phase 3 | Completed | Pain, Postoperative | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02395653) |
| March 17, 2015 | NCT02389907 | Association Between Patients' Perceptions of Success in Post-op Pain Management and Overall Experience With Care | The Medicines Company | Observational | Withdrawn | Postoperative Pain | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02389907) |
| November 8, 2013 | NCT01979445 | Cangrelor to Clopidogrel or Prasugrel Transition Study | The Medicines Company | Phase 2 | Completed | Coronary Artery Disease (CAD) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01979445) |
| August 1, 2013 | NCT01913483 | ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial | The Medicines Company | Phase 3 | Terminated | Peripheral Endovascular Interventions, Bleeding | 732 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01913483) |
| May 22, 2013 | NCT01860105 | Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation | The Medicines Company | Phase 1 | Completed | Pharmacokinetics and Pharmacodynamics in Healthy Volunteers | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01860105) |
| May 13, 2013 | NCT01852019 | Cangrelor Prasugrel Transition Study | The Medicines Company | Phase 2 | Completed | Coronary Artery Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01852019) |
| January 11, 2013 | NCT01766466 | Cangrelor Ticagrelor Transition Study | The Medicines Company | Phase 2 | Completed | Coronary Artery Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01766466) |
| July 27, 2012 | NCT01651780 | Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH | The Medicines Company | Phase 3 | Completed | Severe Aortic Stenosis, Transcatheter Aortic Valve Replacement, Aortic Valve Replacement | 803 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01651780) |
| February 17, 2012 | NCT01535222 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft... | The Medicines Company | Phase 2 | Completed | Coronary Artery Bypass Graft, Cardiopulmonary Bypass | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01535222) |
| February 9, 2012 | NCT01530399 | Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery | The Medicines Company | Phase 2 | Terminated | Bleeding | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01530399) |
| July 5, 2010 | NCT01156571 | A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI)... | The Medicines Company | Phase 3 | Completed | Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome | 11,145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01156571) |
| March 16, 2010 | NCT01087723 | European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial | The Medicines Company | Phase 3 | Completed | Acute Coronary Syndrome | 2,198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01087723) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 1/2 | 1 |
| Phase 2 | 12 |
| Phase 3 | 27 |
| Phase 4 | 3 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 42 |
| Terminated | 5 |
| Withdrawn | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertension | 10 |
| Acute Coronary Syndrome | 7 |
| Hemorrhage | 4 |
| ST Elevation Myocardial Infarction | 4 |
| Myocardial Infarction | 3 |
| Thrombosis | 3 |
| Hypercholesterolemia | 3 |
| Coronary Artery Disease | 3 |
| Atherosclerosis | 3 |
| Non-ST Elevated Myocardial Infarction | 2 |
| Pain, Postoperative | 2 |
| Cardiovascular Diseases | 2 |
| Cellulitis | 1 |
| Dyspnea | 1 |
| Thrombocytopenia | 1 |
| Heart Diseases | 1 |
| Agnosia | 1 |
| Aortic Valve Stenosis | 1 |
| Hyperlipoproteinemia Type II | 1 |
| Diabetes Mellitus | 1 |
| Angina, Unstable | 1 |
| Acute Disease | 1 |
| Renal Insufficiency | 1 |
| Homozygous Familial Hypercholesterolemia | 1 |
| Heart Failure | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Charter schools in the United States](https://specstream.ai/data/businesses/charter-schools/united-states)
- [Manufacturing consultants in the United States](https://specstream.ai/data/businesses/manufacturing-consultants/united-states)
- [Water purification companies in the United States](https://specstream.ai/data/businesses/water-purification-companies/united-states)
- [Excavation contractors in the United States](https://specstream.ai/data/businesses/excavation-contractors/united-states)
- [Printing equipment suppliers in the United States](https://specstream.ai/data/businesses/printing-equipment-suppliers/united-states)
- [Beauty product suppliers in the United States](https://specstream.ai/data/businesses/beauty-product-suppliers/united-states)
